US/UK/Canada

Share

Contacts

  • Malene Brondberg

    VP, Investor Relations and Corporate Communications


    Paternoster House, 65 St. Paul’s Churchyard, London EC4M 8AB, UK
    +47 22 18 33 01
    +44 7561 431 762
    +47 22 58 00 07
    http://www.nordicnanovector.com
    • Pick a time period -

    Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37

    Oslo, Norway, 30 July 2020 Nordic Nanovector ASA (OSE: NANO) is pleased to announce the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212. Alpha37 has completed preclinical development, during which it demonstrated promising immunogenicity, biodistribution and

    Nordic Nanovector ASA - share capital increase registered

    Nordic Nanovector ASA - share capital increase registered Oslo, Norway, 1 July 2020 Reference is made to the stock exchange notice by Nordic Nanovector ASA ("NANO"), of 7 May 2020, regarding the share capital increase in relation to certain board members’ exercise of RSUs. The issuance of 18,579 new shares has been registered with the Norwegian Register of Business Enterprises. Following registration, the share capital of NANO is NOK 13,232,388.40 divided into 66,161,942 shares, each with a nominal value of NOK 0.20. IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762

    Nordic Nanovector ASA: Allocation of restricted stock unites (RSUs) to the board of directors

    Oslo, Norway, 1 July 2020     Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANO) annual general meeting held on 10 June 2020 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2020 to the annual general meeting in 2021, in the form of RSUs.   The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a

    Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population

    Oslo, Norway, 30 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food and Drug Administration (FDA). PARADIGME is the company’s ongoing pivotal, global, randomised Phase 2b trial investigating Betalutin® ([177]Lu-lilotomab satetraxetan) as a single administration in 3[rd]-line relapsed/refractory

    Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma

    Oslo, Norway, 29 June 2020 Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® ([177]Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior systemic therapies. Nordic Nanovector is evaluating the opportunity to develop Betalutin® as a single-agent treatment for MZL, a rare type of non-Hodgkin’s lymphoma (NHL). Betalutin® has demonstrated a very promising clinical effect in nine

    Nordic Nanovector ASA: Annual General Meeting held

    Oslo, Norway, 10 June 2020 The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 10 June 2020 in Oslo, Norway. All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 20 May 2020. The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact: Malene Brondberg, CFO Cell: +44 7561 431 762 Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/

    Nordic Nanovector to Present at Upcoming Jefferies Virtual Healthcare Conference and ABG Sundal Collier Virtual Oncology Seminar

    Oslo, Norway, 2 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that members of its management team will present at Jefferies Virtual Healthcare Conference, taking place 2-4 June 2020. Nordic Nanovector will also present at ABG Sundal Collier Virtual Oncology Seminar 10 June 2020. Presentations details are as follows: Jefferies Virtual Healthcare ConferenceDate: Tuesday, 2 June 2020Time: 16:30 CET ABG Sundal Collier Virtual Oncology SeminarDate: Wednesday, 10 June 2020Time: 10:25 CET The company presentation will be available on Nordic Nanovector’s Investors

    Nordic Nanovector ASA: Resultat for første kvartal

    Nordic Nanovector ASA (OSE: NANO) publiserer i dag sine resultater for første kvartal 2020. Selskapets ledelse vil presentere resultatene i en webcast klokken 08:30. En lenke til webcast og presentasjon publiseres på selskapets nettside (www.nordicnanovector.com). - Til tross for flere utfordringer har den nye ledelsen sammen med styret og alle våre ansatte gjennomført en fullstendig strategisk vurdering og implementert en handlingsplan basert på konklusjonene. Med en tydelig prioritering av PARADIGME og en kontantbeholdning som skal holde inn i 2021, mener jeg vi er godt posisjonert for

    Nordic Nanovector ASA: Results for the First Quarter 2020

    Oslo, Norway, 26 May 2020 Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2020. A presentation by Nordic Nanovector’s senior management team will take place today via a webcast at 08:30 am CET. A link to the webcast and a presentation is available from the company's homepage (www.nordicnanovector.com). Lars Nieba, interim CEO of Nordic Nanovector, said: “Despite a number of significant challenges, the new senior management team together with the Board and all our employees have moved decisively to conduct a thorough strategic review and to implement an

    Nordic Nanovector ASA: Notice of Annual General Meeting on 10 June 2020

    Oslo, Norway, 20 May 2020 Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 10 June 2020, at 10:00 hours CEST at Thon Hotel Slottsparken, Wergelandsveien 5 in Oslo. Due to the restrictions caused by COVID-19 and the advice from the Norwegian government in connection therewith, all shareholders are encouraged to exercise their shareholder rights without physical attendance at the general meeting, either through advance electronically voting through VPS Investor Services or by using the enclosed proxy form to provide proxy to the Chairman Jan

    Nordic Nanovector ASA Announces Proposed Change of the Nomination Committee

    NANO - Notice of AGM 2020  Oslo, Norway, 20 May 2020Nordic Nanovector ASA (OSE: NANO) announces that its Nomination Committee has nominated Mr. Pål Erik Robinson for election as a member of the Nomination Committee at the Company's upcoming Annual General Meeting, as Mr. Olav Steinnes, who has served as a member of the Nomination Committee since November 2014, has decided not to stand for re-election. Mr. Robinson has for the last 18 years been owner and managing director of RO Invest AS. RO Invest AS is a private

    Nordic Nanovector ASA: Invitation to First Quarter 2020 Results Webcast

    Oslo, Norway, 19 May 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the first quarter 2020 on Tuesday, 26 May 2020. A presentation by Nordic Nanovector’s senior management team will take place via a webcast at 08:30 am CET on the same day. A link to the webcast and a presentation will be uploaded to the company's homepage (www.nordicnanovector.com) at 07:00 am CET on Tuesday 26 May. For further information, please contact: IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark

    Nordic Nanovector’s Betalutin® Receives Positive Opinion for Orphan Drug Designation from EMA for Marginal Zone Lymphoma (MZL)

    Oslo, Norway, 14 May 2020 Nordic Nanovector ASA (OSE: NANO) today announces that Betalutin® ([177]Lu lilotomab satetraxetan) has received a positive opinion from the European Medicines Agency (EMA) on the application for orphan drug designation for the treatment of marginal zone lymphoma (MZL). The positive opinion is expected to be adopted by the European Commission shortly. In the LYMRIT 37-01 Phase 1/2a trial, Betalutin® showed a highly encouraging 78% overall response rate (ORR) and 44% complete response (CR) in the MZL patient group (n=9) – the highest response rates of any

    Nordic Nanovector ASA: Increase of share capital

    Oslo, Norway, 7 May 2020   Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 9,761 RSUs. The RSU’s were issued to them in May 2019 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2019 to the annual general meeting in 2020 in RSUs. In addition, board member Hilde Steineger has resolved to settle a total number of 8,818 RSUs previously issued as remuneration under the RSU-program. Each RSU gives the right to

    Nordic Nanovector Announces US Patent Granted Covering the Use of Betalutin® to Sensitise B-Cell Cancer Cells to CD20 Immunotherapy

    Oslo, Norway, 5 May 2020 Nordic Nanovector ASA (OSE:) is pleased to announce the grant of a US patent covering the use of Betalutin® ([177]Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estate around the use of Betalutin® in combination with other drugs that target antigens presented on the surface of tumour cells in patients with B-cell malignancies, such as Non-Hodgkin’s Lymphoma (NHL). The company believes that the combination of

    Nordic Nanovector Announces Changes to its Executive Management Team

    Oslo, Norway, 4 May 2020 Nordic Nanovector ASA (OSE: NANO) today announces changes to its Executive Management Team. As a result of the cost-saving initiatives announced on 2 April 2020, the Board of Directors of Nordic Nanovector has restructured the senior management team. The restructuring has resulted in the number of executives being reduced from nine to seven. Malene Brondberg, Vice President Investor Relations and Corporation Communications, has been appointed CFO, effective 1 May, reporting to Lars Nieba, interim CEO. Malene Brondberg will in her new role as CFO be

    Nordic Nanovector Announces New Date for Annual General Meeting

    Oslo, Norway, 8 April 2020 Nordic Nanovector ASA (OSE:) today announces a new date for its Annual General Meeting (AGM) as a result of the impact of the ongoing COVID-19 pandemic. The AGM will now be held on 10 June at 10.00 CET 2020 (previous 30 April 2020). All other details of the AGM, including the resolutions to be proposed at the meeting, remain unchanged from those notified to shareholders on 19 March 2020.   For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@

    Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021

    Oslo, Norway, 1 April 2020 Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial with Betalutin® in advanced follicular lymphoma (FL) as well as to extend its cash runway into 2021. A webcast will take place on Thursday 2 April at 10:00 am CET. Details below. At the time of the Q4 results in February, the company noted that it would, under its new management, critically assess the current strategy and clinical trial operations. Following this assessment several key development decisions have been

    Nordic Nanovector ASA publishes 2019 Annual Report

    Oslo, Norway, 27 March 2020 On 26 March 2020, the Board of Directors of Nordic Nanovector ASA approved the company’s financial statements for 2019. The company’s 2019 Annual Report is attached and available on Nordic Nanovector ASA’s website: www.nordicnanovector.com. For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email:

    Nordic Nanovector ASA – allocation of PSUs

    Oslo, Norway, 24 March 2020 The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 24 March 2020 decided to grant 561,500 Performance Share Units ("PSUs") to employees in accordance with the authorisation granted at the Annual General Meeting held on 25 April 2019 (the "AGM"). The terms and conditions of the PSUs, which are part of the Company's long-term incentive plan for employees, are described on pages 18-25 in the Company's annual report for 2018. The PSUs are granted without consideration. The PSUs are non-transferable and will vest

    Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer

    Oslo, Norway, 23 March 2020 Nordic Nanovector ASA (OSE: NANO) announces that Dr Dominic Smethurst has been appointed Interim Chief Medical Officer with immediate effect. Dr Smethurst replaces Dr Lisa Rojkjaer, MD, who after a handover period will leave Nordic Nanovector to pursue other career opportunities. Dr Smethurst is an experienced drug development physician having led complex global clinical trials within oncology. Previously, Dr Smethurst was the Group Medical Director of Tusk Therapeutics, where he played a key role in the development of this private immuno-oncology company

    Nordic Nanovector ASA Announces Proposed Board Change

    Oslo, Norway, 19 March 2020 Nordic Nanovector ASA (OSE: NANO) announces that its Nomination Committee has nominated Dr Karin Meyer, PhD for election as a Non-executive Director at the Company’s Annual General Meeting.   The company also notes that Gisela Schwab, MD, who has served as a Non-executive Director on the Board of Nordic Nanovector since March 2015 has, due to increased workload, responsibilities and competing priorities, decided not to stand for re-election at the upcoming AGM. Karin Meyer, PhD, has been nominated for election as a Non-executive Director at the AGM. Dr

    Nordic Nanovector ASA - Financial calendar

    Oslo, Norway, 10 March 2020   Financial calendar for Nordic Nanovector ASA   FINANCIAL YEAR 2019 27.03.2020 - Annual Report   FINANCIAL YEAR 2020 27.08.2020 - Half-yearly Report 30.04.2020 - Annual General Meeting   26.05.2020 - Quarterly Report - Q1 19.11.2020 - Quarterly Report - Q3   For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate CommunicationsCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe